Shots:

• EMA’s COMP has granted a positive opinion for an ODD status to its PBP1510 for the treatment of pancreatic cancer. COMP’s positive will be sent to the EC which is expected to grant the orphan designation within 30 days
• The ODD allows the Prestige to get exclusive rights to commercialize for 10yrs.- following the regulatory approval in the future
• PBP1510 is an anti-PAUF mAb for pancreatic cancer in P-I stages and has already received the US FDA’s and the Korean MFDS’ ODD status in Jun & July’2020 respectively
  
    Ref: B3C Newswire | Image: Michael J Williams- DMD- PC